Active Ingredient(s): Bepotastine Besilate
FDA Approved: * September 8, 2009
Pharm Company: * ISTA PHARMS
Category: Allergies, Cough & Cold

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Bepreve Overview

Bepotastine (Talion, Bepreve) is a 2nd generation antihistamine.[1] It was approved in Japan for use in the treatment of allergic rhinitis and urticaria/pruritus in July 2000 and January 2002, respectively. It is currently marketed in the United States as an eye drop under the brand-name Bepreve, by ISTA Pharmaceuticals, a subsidiary of Bausch + Lomb. Contents 1 Pharmacology 2 Marketing history 3 Sales and patents 4 Clinical trials 5 References Pharmacology Bepotastine ...

Read more Bepreve Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Bepreve Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Bepotastine Besilate
  • Solution: 1.5%, 15%
  • Solution/drops: 1.5%, 1.50%
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Bepreve: (3 results)

Sorted by National Drug Code
  • 24208-629 Bepreve 15 mg/ml Ophthalmic Solution/ Drops by Bausch & Lomb Incorporated
  • 54868-6299 Bepreve 15 mg/ml Ophthalmic Solution/ Drops by Physicians Total Care, Inc.
  • 67425-007 Bepreve 15 mg/ml Ophthalmic Solution/ Drops by Ista Pharmaceuticals, Inc

Other drugs which contain Bepotastine Besilate or a similar ingredient: (1 result)